cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Arrowhead Pharmaceuticals Inc
21 own
21 watching
Current Price
$28.19
$-0.75
(-2.59%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,932.95M
52-Week High
52-Week High
39.83000
52-Week Low
52-Week Low
20.67000
Average Volume
Average Volume
0.82M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2,932.95M
icon52-Week High39.83000
icon52-Week Low20.67000
iconAverage Volume0.82M
iconDividend Yield--
iconP/E Ratio--
What does the Arrowhead Pharmaceuticals Inc do?
Arrowhead Pharmaceuticals, Inc. develops novel drugs to treat intractable diseases in the United States. Its pre-clinical stage drug candidates include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT to treat liver disease associated with alpha-1 antitrypsin deficiency; ARO-LPA to reduce production of apolipoprotein A; ARO-AMG1, which is developed against an undisclosed genetically validated cardiovascular target; and ARO-F12, a potential treatment for factor 12 mediated diseases, such as hereditary angioedema and thromboembolic disorders. The company also develops ARO-HIF2, a drug candidate for the treatment of clear cell renal cell carcinoma. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreements with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Read More
How much money does Arrowhead Pharmaceuticals Inc make?
News & Events about Arrowhead Pharmaceuticals Inc.
Business Wire
1 year ago
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented updated results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD). The SEQUOIA Phase 2 data are consistent...
TipRanks Financial Blog
1 year ago
In a report released yesterday, Akinori Ueda from Goldman Sachs maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR Research Report), with... In a report released yesterday, Akinori Ueda from Goldman Sachs maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR &#8211...
PR Newswire
1 year ago
Thinking about buying stock in XPO, Virios Therapeutics, Arrowhead Pharmaceuticals, Petros Pharmaceuticals, or Citius Pharmaceuticals? Thinking about buying stock in XPO, Virios Therapeutics, Arrowhead Pharmaceuticals, Petros Pharmaceuticals, or Citius Pharmaceuticals? PR Newswire NEW YORK, April...
Fool.com Headlines
1 year ago
The clinical-stage drug developer is attracting a lot of positive attention from investment bank analysts.Are you looking for stocks that can make dramatic moves in a short amount of time? If so, you'll want to check out Arrowhead Pharmaceuticals (NASDAQ: ARWR). SVB Securities, a subsidiary ofSVB ...
Business Wire
1 year ago
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a Research & Development (R&D) Day on June 1, 2023, beginning at 9 a.m. ET in New York City to discuss progress towards the companys 20 in 25 goal to grow its pipeline of RNAi therapeutics that leverage...
Frequently Asked Questions
Frequently Asked Questions
What is Arrowhead Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Arrowhead Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Arrowhead Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Arrowhead Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Arrowhead Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Arrowhead Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Arrowhead Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Arrowhead Pharmaceuticals Inc?
plus_minus_icon
What percentage is Arrowhead Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Arrowhead Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$28.19
$-0.75
(-2.59%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$86.44
$0.46 (0.54 %)
Viking Therapeutics, Inc.
Viking Therapeutics, Inc.
$65.97
$1.29 (1.99 %)
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$1.87
$-0.01 (-0.80 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$3.88
$-0.04 (-0.89 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc.
$86.44
$0.46 (0.54 %)
Viking Therapeutics, Inc.
Viking Therapeutics, Inc.
$65.97
$1.29 (1.99 %)
PROQR THERAPEUTICS NV
PROQR THERAPEUTICS NV
$1.87
$-0.01 (-0.80 %)
Arbutus Biopharma Corporation
Arbutus Biopharma Corporation
$3.88
$-0.04 (-0.89 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00